Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BeOne Medicines AG before investing.

In this article, we go over a few key elements for understanding BeOne Medicines AG’s stock price such as:

• BeOne Medicines AG’s current stock price and volume
• Why BeOne Medicines AG’s stock price changed recently
• Upgrades and downgrades for ONC from analysts
• ONC’s stock price momentum as measured by its relative strength

About BeOne Medicines AG (ONC)

Before we jump into BeOne Medicines AG’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Want to learn more about BeOne Medicines AG’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BeOne Medicines AG.

BeOne Medicines AG’s Stock Price as of Market Close

As of May 08, 2026, 10:46 AM, CST, BeOne Medicines AG’s stock price was $318.060.

BeOne Medicines AG is up 0.33% from its previous closing price of $317.000.

During the last market session, BeOne Medicines AG’s stock traded between $314.935 and $318.060. Currently, there are approximately 110.96 million shares outstanding for BeOne Medicines AG.

BeOne Medicines AG’s price-earnings (P/E) ratio is currently at 72.0, which is high compared to the Biotechnology industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

BeOne Medicines AG Stock Price History

BeOne Medicines AG’s (ONC) price is currently up 7.72% so far this month.

During the month of May, BeOne Medicines AG’s stock price has reached a high of $318.060 and a low of $291.660.

Over the last year, BeOne Medicines AG has hit prices as high as $385.220 and as low as $218.310. Year to date, BeOne Medicines AG’s stock is up 4.69%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BeOne Medicines AG Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 0 analysts who downgraded BeOne Medicines AG’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate BeOne Medicines AG’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BeOne Medicines AG’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BeOne Medicines AG’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BeOne Medicines AG (ONC) by visiting AAII Stock Evaluator.

Relative Price Strength of BeOne Medicines AG

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, BeOne Medicines AG has a weighted four-quarter relative price strength of -1.66%, which translates to a Momentum Score of 53 and is considered to be Average.

Want to learn more about how BeOne Medicines AG is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BeOne Medicines AG Stock Price: Bottom Line

As of May 8, 2026, BeOne Medicines AG’s stock price is $318.060, which is up 0.33% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BeOne Medicines AG stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BeOne Medicines AG before investing.

In this article, we go over a few key elements for understanding BeOne Medicines AG’s stock price such as:

• BeOne Medicines AG’s current stock price and volume
• Why BeOne Medicines AG’s stock price changed recently
• Upgrades and downgrades for ONC from analysts
• ONC’s stock price momentum as measured by its relative strength

About BeOne Medicines AG (ONC)

Before we jump into BeOne Medicines AG’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Want to learn more about BeOne Medicines AG’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BeOne Medicines AG.

BeOne Medicines AG’s Stock Price as of Market Close

As of May 08, 2026, 10:46 AM, CST, BeOne Medicines AG’s stock price was $318.060.

BeOne Medicines AG is up 0.33% from its previous closing price of $317.000.

During the last market session, BeOne Medicines AG’s stock traded between $314.935 and $318.060. Currently, there are approximately 110.96 million shares outstanding for BeOne Medicines AG.

BeOne Medicines AG’s price-earnings (P/E) ratio is currently at 72.0, which is high compared to the Biotechnology industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

BeOne Medicines AG Stock Price History

BeOne Medicines AG’s (ONC) price is currently up 7.72% so far this month.

During the month of May, BeOne Medicines AG’s stock price has reached a high of $318.060 and a low of $291.660.

Over the last year, BeOne Medicines AG has hit prices as high as $385.220 and as low as $218.310. Year to date, BeOne Medicines AG’s stock is up 4.69%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BeOne Medicines AG Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 0 analysts who downgraded BeOne Medicines AG’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate BeOne Medicines AG’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BeOne Medicines AG’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BeOne Medicines AG’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BeOne Medicines AG (ONC) by visiting AAII Stock Evaluator.

Relative Price Strength of BeOne Medicines AG

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, BeOne Medicines AG has a weighted four-quarter relative price strength of -1.66%, which translates to a Momentum Score of 53 and is considered to be Average.

Want to learn more about how BeOne Medicines AG is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BeOne Medicines AG Stock Price: Bottom Line

As of May 8, 2026, BeOne Medicines AG’s stock price is $318.060, which is up 0.33% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BeOne Medicines AG stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BeOne Medicines AG before investing.

In this article, we go over a few key elements for understanding BeOne Medicines AG’s stock price such as:

• BeOne Medicines AG’s current stock price and volume
• Why BeOne Medicines AG’s stock price changed recently
• Upgrades and downgrades for ONC from analysts
• ONC’s stock price momentum as measured by its relative strength

About BeOne Medicines AG (ONC)

Before we jump into BeOne Medicines AG’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Want to learn more about BeOne Medicines AG’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BeOne Medicines AG.

BeOne Medicines AG’s Stock Price as of Market Close

As of May 08, 2026, 10:46 AM, CST, BeOne Medicines AG’s stock price was $318.060.

BeOne Medicines AG is up 0.33% from its previous closing price of $317.000.

During the last market session, BeOne Medicines AG’s stock traded between $314.935 and $318.060. Currently, there are approximately 110.96 million shares outstanding for BeOne Medicines AG.

BeOne Medicines AG’s price-earnings (P/E) ratio is currently at 72.0, which is high compared to the Biotechnology industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

BeOne Medicines AG Stock Price History

BeOne Medicines AG’s (ONC) price is currently up 7.72% so far this month.

During the month of May, BeOne Medicines AG’s stock price has reached a high of $318.060 and a low of $291.660.

Over the last year, BeOne Medicines AG has hit prices as high as $385.220 and as low as $218.310. Year to date, BeOne Medicines AG’s stock is up 4.69%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BeOne Medicines AG Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 0 analysts who downgraded BeOne Medicines AG’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate BeOne Medicines AG’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BeOne Medicines AG’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BeOne Medicines AG’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BeOne Medicines AG (ONC) by visiting AAII Stock Evaluator.

Relative Price Strength of BeOne Medicines AG

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, BeOne Medicines AG has a weighted four-quarter relative price strength of -1.66%, which translates to a Momentum Score of 53 and is considered to be Average.

Want to learn more about how BeOne Medicines AG is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BeOne Medicines AG Stock Price: Bottom Line

As of May 8, 2026, BeOne Medicines AG’s stock price is $318.060, which is up 0.33% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BeOne Medicines AG stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BeOne Medicines AG before investing.

In this article, we go over a few key elements for understanding BeOne Medicines AG’s stock price such as:

• BeOne Medicines AG’s current stock price and volume
• Why BeOne Medicines AG’s stock price changed recently
• Upgrades and downgrades for ONC from analysts
• ONC’s stock price momentum as measured by its relative strength

About BeOne Medicines AG (ONC)

Before we jump into BeOne Medicines AG’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Want to learn more about BeOne Medicines AG’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BeOne Medicines AG.

BeOne Medicines AG’s Stock Price as of Market Close

As of May 08, 2026, 10:46 AM, CST, BeOne Medicines AG’s stock price was $318.060.

BeOne Medicines AG is up 0.33% from its previous closing price of $317.000.

During the last market session, BeOne Medicines AG’s stock traded between $314.935 and $318.060. Currently, there are approximately 110.96 million shares outstanding for BeOne Medicines AG.

BeOne Medicines AG’s price-earnings (P/E) ratio is currently at 72.0, which is high compared to the Biotechnology industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

BeOne Medicines AG Stock Price History

BeOne Medicines AG’s (ONC) price is currently up 7.72% so far this month.

During the month of May, BeOne Medicines AG’s stock price has reached a high of $318.060 and a low of $291.660.

Over the last year, BeOne Medicines AG has hit prices as high as $385.220 and as low as $218.310. Year to date, BeOne Medicines AG’s stock is up 4.69%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BeOne Medicines AG Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 0 analysts who downgraded BeOne Medicines AG’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate BeOne Medicines AG’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BeOne Medicines AG’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BeOne Medicines AG’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BeOne Medicines AG (ONC) by visiting AAII Stock Evaluator.

Relative Price Strength of BeOne Medicines AG

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, BeOne Medicines AG has a weighted four-quarter relative price strength of -1.66%, which translates to a Momentum Score of 53 and is considered to be Average.

Want to learn more about how BeOne Medicines AG is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BeOne Medicines AG Stock Price: Bottom Line

As of May 8, 2026, BeOne Medicines AG’s stock price is $318.060, which is up 0.33% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BeOne Medicines AG stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BeOne Medicines AG before investing.

In this article, we go over a few key elements for understanding BeOne Medicines AG’s stock price such as:

• BeOne Medicines AG’s current stock price and volume
• Why BeOne Medicines AG’s stock price changed recently
• Upgrades and downgrades for ONC from analysts
• ONC’s stock price momentum as measured by its relative strength

About BeOne Medicines AG (ONC)

Before we jump into BeOne Medicines AG’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Want to learn more about BeOne Medicines AG’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BeOne Medicines AG.

BeOne Medicines AG’s Stock Price as of Market Close

As of May 08, 2026, 10:46 AM, CST, BeOne Medicines AG’s stock price was $318.060.

BeOne Medicines AG is up 0.33% from its previous closing price of $317.000.

During the last market session, BeOne Medicines AG’s stock traded between $314.935 and $318.060. Currently, there are approximately 110.96 million shares outstanding for BeOne Medicines AG.

BeOne Medicines AG’s price-earnings (P/E) ratio is currently at 72.0, which is high compared to the Biotechnology industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

BeOne Medicines AG Stock Price History

BeOne Medicines AG’s (ONC) price is currently up 7.72% so far this month.

During the month of May, BeOne Medicines AG’s stock price has reached a high of $318.060 and a low of $291.660.

Over the last year, BeOne Medicines AG has hit prices as high as $385.220 and as low as $218.310. Year to date, BeOne Medicines AG’s stock is up 4.69%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BeOne Medicines AG Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 0 analysts who downgraded BeOne Medicines AG’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate BeOne Medicines AG’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BeOne Medicines AG’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BeOne Medicines AG’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BeOne Medicines AG (ONC) by visiting AAII Stock Evaluator.

Relative Price Strength of BeOne Medicines AG

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, BeOne Medicines AG has a weighted four-quarter relative price strength of -1.66%, which translates to a Momentum Score of 53 and is considered to be Average.

Want to learn more about how BeOne Medicines AG is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BeOne Medicines AG Stock Price: Bottom Line

As of May 8, 2026, BeOne Medicines AG’s stock price is $318.060, which is up 0.33% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BeOne Medicines AG stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BeOne Medicines AG before investing.

In this article, we go over a few key elements for understanding BeOne Medicines AG’s stock price such as:

• BeOne Medicines AG’s current stock price and volume
• Why BeOne Medicines AG’s stock price changed recently
• Upgrades and downgrades for ONC from analysts
• ONC’s stock price momentum as measured by its relative strength

About BeOne Medicines AG (ONC)

Before we jump into BeOne Medicines AG’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Want to learn more about BeOne Medicines AG’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BeOne Medicines AG.

BeOne Medicines AG’s Stock Price as of Market Close

As of May 08, 2026, 10:46 AM, CST, BeOne Medicines AG’s stock price was $318.060.

BeOne Medicines AG is up 0.33% from its previous closing price of $317.000.

During the last market session, BeOne Medicines AG’s stock traded between $314.935 and $318.060. Currently, there are approximately 110.96 million shares outstanding for BeOne Medicines AG.

BeOne Medicines AG’s price-earnings (P/E) ratio is currently at 72.0, which is high compared to the Biotechnology industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

BeOne Medicines AG Stock Price History

BeOne Medicines AG’s (ONC) price is currently up 7.72% so far this month.

During the month of May, BeOne Medicines AG’s stock price has reached a high of $318.060 and a low of $291.660.

Over the last year, BeOne Medicines AG has hit prices as high as $385.220 and as low as $218.310. Year to date, BeOne Medicines AG’s stock is up 4.69%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BeOne Medicines AG Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 0 analysts who downgraded BeOne Medicines AG’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate BeOne Medicines AG’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BeOne Medicines AG’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BeOne Medicines AG’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BeOne Medicines AG (ONC) by visiting AAII Stock Evaluator.

Relative Price Strength of BeOne Medicines AG

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, BeOne Medicines AG has a weighted four-quarter relative price strength of -1.66%, which translates to a Momentum Score of 53 and is considered to be Average.

Want to learn more about how BeOne Medicines AG is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BeOne Medicines AG Stock Price: Bottom Line

As of May 8, 2026, BeOne Medicines AG’s stock price is $318.060, which is up 0.33% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BeOne Medicines AG stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BeOne Medicines AG before investing.

In this article, we go over a few key elements for understanding BeOne Medicines AG’s stock price such as:

• BeOne Medicines AG’s current stock price and volume
• Why BeOne Medicines AG’s stock price changed recently
• Upgrades and downgrades for ONC from analysts
• ONC’s stock price momentum as measured by its relative strength

About BeOne Medicines AG (ONC)

Before we jump into BeOne Medicines AG’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Want to learn more about BeOne Medicines AG’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BeOne Medicines AG.

BeOne Medicines AG’s Stock Price as of Market Close

As of May 08, 2026, 10:46 AM, CST, BeOne Medicines AG’s stock price was $318.060.

BeOne Medicines AG is up 0.33% from its previous closing price of $317.000.

During the last market session, BeOne Medicines AG’s stock traded between $314.935 and $318.060. Currently, there are approximately 110.96 million shares outstanding for BeOne Medicines AG.

BeOne Medicines AG’s price-earnings (P/E) ratio is currently at 72.0, which is high compared to the Biotechnology industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

BeOne Medicines AG Stock Price History

BeOne Medicines AG’s (ONC) price is currently up 7.72% so far this month.

During the month of May, BeOne Medicines AG’s stock price has reached a high of $318.060 and a low of $291.660.

Over the last year, BeOne Medicines AG has hit prices as high as $385.220 and as low as $218.310. Year to date, BeOne Medicines AG’s stock is up 4.69%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BeOne Medicines AG Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 0 analysts who downgraded BeOne Medicines AG’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate BeOne Medicines AG’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BeOne Medicines AG’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BeOne Medicines AG’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BeOne Medicines AG (ONC) by visiting AAII Stock Evaluator.

Relative Price Strength of BeOne Medicines AG

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, BeOne Medicines AG has a weighted four-quarter relative price strength of -1.66%, which translates to a Momentum Score of 53 and is considered to be Average.

Want to learn more about how BeOne Medicines AG is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BeOne Medicines AG Stock Price: Bottom Line

As of May 8, 2026, BeOne Medicines AG’s stock price is $318.060, which is up 0.33% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BeOne Medicines AG stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate BeOne Medicines AG before investing.

In this article, we go over a few key elements for understanding BeOne Medicines AG’s stock price such as:

• BeOne Medicines AG’s current stock price and volume
• Why BeOne Medicines AG’s stock price changed recently
• Upgrades and downgrades for ONC from analysts
• ONC’s stock price momentum as measured by its relative strength

About BeOne Medicines AG (ONC)

Before we jump into BeOne Medicines AG’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Want to learn more about BeOne Medicines AG’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about BeOne Medicines AG.

BeOne Medicines AG’s Stock Price as of Market Close

As of May 08, 2026, 10:46 AM, CST, BeOne Medicines AG’s stock price was $318.060.

BeOne Medicines AG is up 0.33% from its previous closing price of $317.000.

During the last market session, BeOne Medicines AG’s stock traded between $314.935 and $318.060. Currently, there are approximately 110.96 million shares outstanding for BeOne Medicines AG.

BeOne Medicines AG’s price-earnings (P/E) ratio is currently at 72.0, which is high compared to the Biotechnology industry median of 20.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

BeOne Medicines AG Stock Price History

BeOne Medicines AG’s (ONC) price is currently up 7.72% so far this month.

During the month of May, BeOne Medicines AG’s stock price has reached a high of $318.060 and a low of $291.660.

Over the last year, BeOne Medicines AG has hit prices as high as $385.220 and as low as $218.310. Year to date, BeOne Medicines AG’s stock is up 4.69%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused BeOne Medicines AG Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 07, 2026, there were 0 analysts who downgraded BeOne Medicines AG’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate BeOne Medicines AG’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on BeOne Medicines AG’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

BeOne Medicines AG’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about BeOne Medicines AG (ONC) by visiting AAII Stock Evaluator.

Relative Price Strength of BeOne Medicines AG

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 07, 2026, BeOne Medicines AG has a weighted four-quarter relative price strength of -1.66%, which translates to a Momentum Score of 53 and is considered to be Average.

Want to learn more about how BeOne Medicines AG is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

BeOne Medicines AG Stock Price: Bottom Line

As of May 8, 2026, BeOne Medicines AG’s stock price is $318.060, which is up 0.33% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like BeOne Medicines AG stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.